Investigative Urology - Results from #6060

Mechanisms and urodynamic effects of a potent and selective EP4 receptor antagonist, MF191, on cyclophosphamide and prostaglandin E(2) -induced bladder overactivity in rats - Abstract May 22, 2012

Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer - Abstract May 22, 2012

Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma - Abstract May 21, 2012

BMP-2 inhibits tumor growth of human renal cell carcinoma and induces bone formation - Abstract May 21, 2012

H-ras mutation detection in bladder cancer by COLD-PCR analysis and direct sequencing - Abstract May 21, 2012

Bladder expression of CD cell surface antigens and cell-type-specific transcriptomes - Abstract May 21, 2012

miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer - Abstract May 21, 2012

Apigenin inhibits cell migration through MAPK pathways in human bladder smooth muscle cells - Abstract May 21, 2012

Slug contributes to cadherin switch and malignant progression in muscle-invasive bladder cancer development - Abstract May 21, 2012

Exploring molecular genetics of bladder cancer: lessons learned from mouse models - Abstract May 21, 2012

Targeting angiogenesis for the treatment of prostate cancer - Abstract May 18, 2012

Alterations of global histone H4K20 methylation during prostate carcinogenesis - Abstract May 18, 2012

DNA Repair System and Prostate Cancer Progression: The Role of NBS1 Polymorphism (rs1805794) - Abstract May 18, 2012

Targeting bone remodeling by isoflavone and 3,3'-diindolylmethane in the context of prostate cancer bone metastasis - Abstract May 18, 2012

Caveolin-1 and prostate cancer progression - Abstract May 18, 2012

The receptor tyrosine kinase Axl is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target - Abstract May 18, 2012

Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer - Abstract May 18, 2012

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer - Abstract May 18, 2012

Perturbation of the EphA2-EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites - Abstract May 17, 2012

Prostate cancers detected during 5α-reductase inhibitor use are smaller, de-differentiated, but confined when compared to controls - Abstract May 17, 2012

Page 304 of 346